Top

Published in:

Open Access 01-12-2024 | Arterial Diseases | Research

Characterizing the metabolic divide: distinctive metabolites differentiating CAD-T2DM from CAD patients

Authors: Yingjian Liu, Ju-e Liu, Huafeng He, Min Qin, Heping Lei, Jinxiu Meng, Chen Liu, Xiaoping Chen, Wenwei Luo, Shilong Zhong

Published in: Cardiovascular Diabetology | Issue 1/2024

Abstract

Objective

To delineate the metabolomic differences in plasma samples between patients with coronary artery disease (CAD) and those with concomitant CAD and type 2 diabetes mellitus (T2DM), and to pinpoint distinctive metabolites indicative of T2DM risk.

Method

Plasma samples from CAD and CAD-T2DM patients across three centers underwent comprehensive metabolomic and lipidomic analyses. Multivariate logistic regression was employed to discern the relationship between the identified metabolites and T2DM risk. Characteristic metabolites' metabolic impacts were further probed through hepatocyte cellular experiments. Subsequent transcriptomic analyses elucidated the potential target sites explaining the metabolic actions of these metabolites.

Results

Metabolomic analysis revealed 192 and 95 significantly altered profiles in the discovery (FDR < 0.05) and validation (P < 0.05) cohorts, respectively, that were associated with T2DM risk in univariate logistic regression. Further multivariate regression analyses identified 22 characteristic metabolites consistently associated with T2DM risk in both cohorts. Notably, pipecolinic acid and L-pipecolic acid, lysine derivatives, exhibited negative association with CAD-T2DM and influenced cellular glucose metabolism in hepatocytes. Transcriptomic insights shed light on potential metabolic action sites of these metabolites.

Conclusions

This research underscores the metabolic disparities between CAD and CAD-T2DM patients, spotlighting the protective attributes of pipecolinic acid and L-pipecolic acid. The comprehensive metabolomic and transcriptomic findings provide novel insights into the mechanism research, prophylaxis and treatment of comorbidity of CAD and T2DM.

Available only for authorised users

Wu T, Qiao S, Shi C, Wang S, Ji G. Metabolomics window into diabetic complications. J Diabetes Invest. 2018;9:244–55.CrossRef

Lima EG, Hueb W, Garcia RMR, Pereira AC, Soares PR, Favarato D, et al. Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the medicine, angioplasty, or surgery study II (MASS II) trial. Am Heart J. 2013;166:250–7.PubMedCrossRef

Shen M, Xie Q, Zhang R, Yu C, Xiao P. Metabolite-assisted models improve risk prediction of coronary heart disease in patients with diabetes. Front Pharmacol. 2023. https://doi.org/10.3389/fphar.2023.1175021.CrossRefPubMedPubMedCentral

Arnold SV, Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the american heart association. Circulation. 2020;141:e779-806.PubMedCrossRef

Goodarzi MO, Rotter JI. Genetics insights in the relationship between type 2 diabetes and coronary heart disease. Circ Res. 2020;126:1526–48.PubMedPubMedCentralCrossRef

Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus | Circulation. https://www.ahajournals.org/doi/https://doi.org/10.1161/circulationaha.105.539528

PGC-1α, glucose metabolism and type 2 diabetes mellitus—Abstract—Europe PMC. https://europepmc.org/article/med/27094040

Xiao H, Ma Y, Zhou Z, Li X, Ding K, Wu Y, et al. Disease patterns of coronary heart disease and type 2 diabetes harbored distinct and shared genetic architecture. Cardiovasc Diabetol. 2022;21:276.PubMedPubMedCentralCrossRef

Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20:685–95.PubMedCrossRef

10.

Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell. 2008;134:714–7. PubMedCrossRef

11.

Wishart DS, Guo A, Oler E, Wang F, Anjum A, Peters H, et al. HMDB 5.0: the human metabolome database for 2022. Nucleic Acids Res. 2021;50:D622-31.PubMedCentralCrossRef

12.

Liu X, Locasale JW. Metabolomics: a primer. Trends Biochem Sci. 2017;42:274–84.PubMedPubMedCentralCrossRef

13.

Metabolomics: beyond biomarkers and towards mechanisms Nature reviews molecular cell Biology. https://www.nature.com/articles/nrm.2016.25

14.

Meikle PJ, Christopher MJ. Lipidomics is providing new insight into the metabolic syndrome and its sequelae. Curr Opin Lipidol. 2011;22:210.PubMedCrossRef

15.

Fan Y, Li Y, Chen Y, Zhao Y-J, Liu L-W, Li J, et al. Comprehensive metabolomic characterization of coronary artery diseases. J Am Coll Cardiol. 2016;68:1281–93.PubMedCrossRef

16.

Roberts LD, Koulman A, Griffin JL. Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. Lancet Diabetes Endocrinol. 2014;2:65–75.PubMedCrossRef

17.

Urpi-Sarda M, Almanza-Aguilera E, Tulipani S, Tinahones FJ, Salas-Salvadó J, Andres-Lacueva C. Metabolomics for biomarkers of type 2 diabetes mellitus: advances and nutritional intervention trends. Curr Cardiovasc Risk Rep. 2015;9:12.CrossRef

18.

Würtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2013;36:648–55.PubMedPubMedCentralCrossRef

19.

Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults – PubMed. https://pubmed.ncbi.nlm.nih.gov/23129134/

20.

Yun H, Sun L, Wu Q, Zong G, Qi Q, Li H, et al. Associations among circulating sphingolipids, β-cell function, and risk of developing type 2 diabetes: a population-based cohort study in China. PLoS Med. 2020;17: e1003451.PubMedPubMedCentralCrossRef

21.

Yousri NA, Suhre K, Yassin E, Al-Shakaki A, Robay A, Elshafei M, et al. Metabolic and metabo-clinical signatures of type 2 diabetes, obesity, retinopathy, and dyslipidemia. Diabetes. 2022;71:184–205.PubMedCrossRef

22.

Chen Z-Z, Gerszten RE. Metabolomics and proteomics in type 2 diabetes. Circ Res. 2020;126:1613–27.PubMedCrossRef

23.

Liu W, Guo P, Dai T, Shi X, Shen G, Feng J. Metabolic interactions and differences between coronary heart disease and diabetes mellitus: a pilot study on biomarker determination and pathogenesis. J Proteome Res. 2021;20:2364–73.PubMedCrossRef

24.

Inubushi T, Kamemura N, Oda M, Sakurai J, Nakaya Y, Harada N, et al. L-tryptophan suppresses rise in blood glucose and preserves insulin secretion in type-2 diabetes mellitus rats. J Nutr Sci Vitaminol. 2012;58:415–22.PubMedCrossRef

25.

Keskin E, Yoldas IH. Fructose consumption correlates with triglyceride-glucose index and glycemic status in healthy adults. Clin Nutr ESPEN. 2022;52:184–9.PubMedCrossRef

26.

Zhou Q, Sun W-W, Chen J-C, Zhang H-L, Liu J, Lin Y, et al. Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ. Nat Commun. 2022;13:4291.PubMedPubMedCentralCrossRef

27.

Cardiac Energy Metabolism in Heart Failure Circulation Research. https://doi.org/10.1161/CIRCRESAHA.121.318241

28.

Amaral N, Okonko DO. Metabolic abnormalities of the heart in type II diabetes. Diab Vasc Dis Res. 2015;12:239–48.PubMedCrossRef

29.

Chen H, Wang Z, Qin M, Zhang B, Lin L, Ma Q, et al. Comprehensive metabolomics identified the prominent role of glycerophospholipid metabolism in coronary artery disease progression. Front Mol Biosci. 2021. https://doi.org/10.3389/fmolb.2021.632950.CrossRefPubMedPubMedCentral

30.

American Diabetes Association. 2 classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2020;44:15–33.CrossRef

31.

Luan H, Ji F, Chen Y, Cai Z. statTarget: a streamlined tool for signal drift correction and interpretations of quantitative mass spectrometry-based omics data. Anal Chim Acta. 2018;1036:66–72.PubMedCrossRef

32.

van den Berg RA, Hoefsloot HCJ, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics. 2006;7:142.PubMedPubMedCentralCrossRef

33.

Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society, Series B. 1996. http://www.socolar.com/Article/Index?aid=100066876931&jid=100000059916

34.

Weingarten A, Turchetti L, Krohn K, Klöting I, Kern M, Kovacs P, et al. Novel genes on rat chromosome 10 are linked to body fat mass, preadipocyte number and adipocyte size. Int J Obes. 2016;40:1832–40.CrossRef

35.

Sirtuin 3 Alleviates Diabetic Cardiomyopathy by Regulating TIGAR and Cardiomyocyte Metabolism Journal of the American Heart Association. https://doi.org/10.1161/JAHA.120.018913

36.

Watanabe S, Fukumori F, Nishiwaki H, Sakurai Y, Tajima K, Watanabe Y. Novel non-phosphorylative pathway of pentose metabolism from bacteria. Sci Rep. 2019;9:155.PubMedPubMedCentralCrossRef

37.

Sakoguchi H, Yoshihara A, Shintani T, Okuma K, Izumori K, Sato M. Growth inhibitory effect of D-arabinose against the nematode Caenorhabditis elegans: discovery of a novel bioactive monosaccharide. Bioorg Med Chem Lett. 2016;26:726–9.PubMedCrossRef

38.

Zhao Q, Zhang A, Zong W, An N, Zhang H, Luan Y, et al. Exploring potential biomarkers and determining the metabolic mechanism of type 2 diabetes mellitus using liquid chromatography coupled to high-resolution mass spectrometry. RSC Adv. 2017;7:44186–98.CrossRef

39.

Ilavenil S, Kim DH, Valan Arasu M, Srigopalram S, Sivanesan R, Choi KC. Phenyllactic acid from lactobacillus plantarum promotes adipogenic activity in 3T3-L1 adipocyte via up-regulation of PPAR-γ2. Molecules. 2015;20:15359–73.PubMedPubMedCentralCrossRef

40.

Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15:412–26.PubMedCrossRef

41.

Vigili de Kreutzenberg S, Avogaro A. The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography. J Endocrinol Invest. 2017;40:627–34.PubMedPubMedCentralCrossRef

42.

Zhang Y, Li Z, Liu X, Chen X, Zhang S, Chen Y, et al. 3-Hydroxybutyrate ameliorates insulin resistance by inhibiting PPARγ Ser273 phosphorylation in type 2 diabetic mice. Signal Transduct Target Ther. 2023;8:190.PubMedPubMedCentralCrossRef

43.

He M. Pipecolic acid in microbes: biosynthetic routes and enzymes. J Ind Microbiol Biotechnol. 2006;33:401–7.PubMedCrossRef

44.

Priyadarsini S, McKay TB, Sarker-Nag A, Allegood J, Chalfant C, Ma J-X, et al. Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma. Exp Eye Res. 2016;153:90–100.PubMedPubMedCentralCrossRef

45.

Ouyang Y, Qiu G, Zhao X, Su B, Feng D, Lv W, et al. Metabolome-Genome-wide association study (mGWAS) reveals novel metabolites associated with future type 2 diabetes risk and susceptibility loci in a case-control study in a Chinese prospective cohort. Global Chall. 2021;5:2000088.CrossRef

46.

Gu X, Al Dubayee M, Alshahrani A, Masood A, Benabdelkamel H, Zahra M, et al. Distinctive metabolomics patterns associated with insulin resistance and type 2 diabetes mellitus. Front Mol Biosci. 2020;7: 609806.PubMedPubMedCentralCrossRef

47.

Chen T, Zheng X, Ma X, Bao Y, Ni Y, Hu C, et al. Tryptophan predicts the risk for future type 2 diabetes. PLoS ONE. 2016;11: e0162192.PubMedPubMedCentralCrossRef

48.

Li Q, You Y, Zeng Y, Wang X, Pan Z, Pang J, et al. Associations between plasma tryptophan and indole-3-propionic acid levels and mortality in patients with coronary artery disease. Am J Clin Nutr. 2022;116:1070–7.PubMedCrossRef

49.

Zhang L, Zhang Y, Ma Z, Zhu Y, Chen Z. Altered amino acid metabolism between coronary heart disease patients with and without type 2 diabetes by quantitative 1H NMR based metabolomics. J Pharm Biomed Anal. 2021;206: 114381.PubMedCrossRef

50.

Rivas-Tumanyan S, Pacheco LS, Haslam DE, Liang L, Tucker KL, Joshipura KJ, et al. Novel plasma metabolomic markers associated with diabetes progression in older puerto ricans. Metabolites. 2022;12:513.PubMedPubMedCentralCrossRef

51.

Shetty SS, Kumari S. Fatty acids and their role in type-2 diabetes (Review). Exp Ther Med. 2021;22:1–6.CrossRef

52.

Wu H-T, Chen W, Cheng K-C, Ku P-M, Yeh C-H, Cheng J-T. Oleic acid activates peroxisome proliferator-activated receptor δ to compensate insulin resistance in steatotic cells. J Nutr Biochem. 2012;23:1264–70.PubMedCrossRef

53.

Palomer X, Pizarro-Delgado J, Barroso E, Vázquez-Carrera M. Palmitic and oleic acid: The Yin and Yang of fatty acids in type 2 diabetes mellitus. Trends Endocrinol Metab. 2018;29:178–90.PubMedCrossRef

54.

Artemis P. Simopoulos. 2023. The Impact of the Bellagio Report on Healthy Agriculture Healthy Nutrition, Healthy People: Scientific and Policy Aspects and the International Network of Centers for Genetics Nutrition and Fitness for Health. Lifestyle Genomics. https://doi.org/10.1159/000375495

55.

van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochimica et Biophysica Acta Biomembranes. 2017;1859:1558–72.PubMedCrossRef

56.

Morze J, Wittenbecher C, Schwingshackl L, Danielewicz A, Rynkiewicz A, Hu FB, et al. Metabolomics and type 2 diabetes risk: an updated systematic review and meta-analysis of prospective cohort studies. Diabetes Care. 2022;45:1013–24.PubMedPubMedCentralCrossRef

57.

Zhou W, Yao Y, Li J, Wu D, Zhao M, Yan Z, et al. TIGAR attenuates high glucose-induced neuronal apoptosis via an autophagy pathway. Front Mol Neurosci. 2019;12:193.PubMedPubMedCentralCrossRef

58.

Penning TM. The aldo-keto reductases (AKRs): overview. Chem Biol Interact. 2015;234:236–46.PubMedCrossRef

59.

Kucharczyk P, Albano G, Deisl C, Ho TM, Bargagli M, Anderegg M, et al. Thiazides attenuate insulin secretion through inhibition of mitochondrial carbonic anhydrase 5b in β -islet cells in mice. J Am Soc Nephrol. 2023;34:1179–90.PubMedCrossRef

60.

Shah GN, Rubbelke TS, Hendin J, Nguyen H, Waheed A, Shoemaker JD, et al. Targeted mutagenesis of mitochondrial carbonic anhydrases VA and VB implicates both enzymes in ammonia detoxification and glucose metabolism. Proc Natl Acad Sci USA. 2013;110:7423–8.PubMedPubMedCentralCrossRef

61.

Charkoftaki G, Wang Y, McAndrews M, Bruford EA, Thompson DC, Vasiliou V, et al. Update on the human and mouse lipocalin (LCN) gene family, including evidence the mouse Mup cluster is result of an “evolutionary bloom.” Hum Genomics. 2019;13:11.PubMedPubMedCentralCrossRef

62.

Tian Y, Yang J, Lan M, Zou T. Construction and analysis of a joint diagnosis model of random forest and artificial neural network for heart failure. Aging (Albany NY). 2020;12:26221–35.PubMedCrossRef

63.

Zhao M, Yuan MM, Yuan L, Huang LL, Liao JH, Yu XL, et al. Chronic folate deficiency induces glucose and lipid metabolism disorders and subsequent cognitive dysfunction in mice. PLoS ONE. 2018;13: e0202910.PubMedPubMedCentralCrossRef

64.

Abdel-Moneim A, Bakery HH, Allam G. The potential pathogenic role of IL-17/Th17 cells in both type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2018;101:287–92.PubMedCrossRef

65.

Tantiwong P, Shanmugasundaram K, Monroy A, Ghosh S, Li M, DeFronzo RA, et al. NF-κB activity in muscle from obese and type 2 diabetic subjects under basal and exercise-stimulated conditions. Am J Physiol Endocrinol Metab. 2010;299:E794-801.PubMedPubMedCentralCrossRef

66.

Raghavan S, Vassy JL, Ho Y, Song RJ, Gagnon DR, Cho K, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8: e011295.PubMedPubMedCentralCrossRef

67.

Ma C-X, Ma X-N, Guan C-H, Li Y-D, Mauricio D, Fu S-B. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21:74.PubMedPubMedCentralCrossRef

68.

Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83.PubMedPubMedCentralCrossRef

Title: Characterizing the metabolic divide: distinctive metabolites differentiating CAD-T2DM from CAD patients
Authors: Yingjian Liu
Ju-e Liu
Huafeng He
Min Qin
Heping Lei
Jinxiu Meng
Chen Liu
Xiaoping Chen
Wenwei Luo
Shilong Zhong
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Arterial Diseases
Type 2 Diabetes
Published in: Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-023-02102-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus

Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance

Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials

Nonlinear relationship between untraditional lipid parameters and the risk of prediabetes: a large retrospective study based on Chinese adults

Associations between cardiometabolic indices and the risk of diabetic kidney disease in patients with type 2 diabetes

Interacting and joint effects of triglyceride-glucose index (TyG) and body mass index on stroke risk and the mediating role of TyG in middle-aged and older Chinese adults: a nationwide prospective cohort study

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage